Table 1 Details on anti-MET agents already available in the clinical scenario for anticancer therapy

Anti-MET monoclonal antibodies

 SAIT301

MET

Advanced MET positive solid tumors

[30]^a

 ARGX-111

MET

MET protein overexpressing advanced cancer

[31]^a

 MetMab (ornatuzumab)

MET

Advanced or metastatic solid tumors

[32–37]^a

 JNJ-61186372

MET-EGFR (bispecific ab)

Advanced NSCLCs

[38–40]^a

 ABT-700

MET

Advanced solid tumors

MET tyrosine kinase inhibitors

 PF-02341066 (crizotinib)

MEK, ALK, ROS 1 (triple inhibitor)

Advanced NSCLCs, gastric cancers, metastatic urothelial cancers,anaplastic large cell lymphoma, colorectal cancers, advanced relapsed/refractory solid tumors, primary CNS tumors

[41–43]^a

 XL-184 (cabozantinib)

MET, VEGFR2 (dual inhibitor)

NSCLCs with brain metastasis, advanced cholangiocarcinoma, metastatic triple negative breast cancers, colorectal cancers, metastatic Merkel cell carcinoma, recurrent endometrial cancers, breast cancers with brain metastasis, metastatic renal cell carcinoma

[44–54]^a

 AZD6094 (Volitinib)

MET

Gastric adenocarcinoma, papillary renal cell carcinoma

[55–58]^a

 GSK1363089 (Foretinib)

MET, VEGFR2 (dual inhibitor)

Papillary renal cell carcinoma, medulloblastoma, metastatic gastric cancers, hepatocellular carcinoma

[59–67]^a

 AMG337

MET

Advanced gastric and esophageal adenocarcinoma, advanced solid tumors

[68–72]^a

 ARQ-197 (tivantinib)

MET (non ATP-competitive)

Relapsed/refractory multiple myeloma; locally advancer or metastatic colorectal cancers; metastatic triple negative breast cancers; childhood relapsed/refractory solid tumors; recurrent/metastatic head and neck cancers; gastric cancers; metastatic solid tumors; metastatic prostate cancers; metastatic or locally advancer kidney cancers; mesothelioma; small cell lung cancers; hepatocellular carcinoma;

[73–90]^a

 INC280 (capmatinib)

MET

NSCLCs; CRCs; HNSCC; advanced solid tumors, hepatocellular carcinoma; metastatic CRCs; metastatic renal cell carcinoma; recurrent glioblastoma; advanced or metastatic melanoma

[91, 92]^a

 EMD 1204831

MET

Advanced solid tumors; advanced hepatocellular carcinoma

[93]^a

 MGCD265

MEK, ALK (dual inhibitor)

Advanced cancers

[94, 95]^a

 MK8033

MET, RON (ATP-competitive dual inhibitor)

Advanced solid tumors

[96]^a

 PF-04217903

MET (ATP-competitive)

Advanced cancers

[97–99]^a